Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Connecticut: below-average open trial sites
1,136 of 3,531 in-state trials are recruiting (32%); below the 37% national average by 5 percentage points.
According to ClinicalTrials.gov-derived indexes, Connecticut sits in the upper half of US states by in-state trial count (#18 of 52 states by registered in-state trial count).
Connecticut: 3,531 US clinical trials with in-state sites, 1,136 recruiting.
Connecticut has 3,531 registered US clinical trials with a study site in-state, 1,136 of them currently recruiting (below the 37% national average by 5 percentage points). 927 of these trials are in Phase 3 (late-stage) and 810 in Phase 2. The most frequently studied condition in Connecticut is Breast Cancer, with 77 linked trials.
Mid-pack research density
Connecticut sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
Connecticut still shows 1,136 recruiting of 3,531 in-state trials (32% open), but below the 37% national average by 5 percentage points, so archived statuses weigh heavier than the national baseline.
- 32%
- open (below national share)
- 1,136
- still recruiting despite cool share
- 810
- Phase 2 rows in this footprint
- 77
- top: Breast Cancer
Recruiting share is below the 37% national average by 5 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Connecticut vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
3,531 Top 35% more indexed trials than 65% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Connecticut on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Connecticut open-enrollment share sits below the national baseline.
1,136 of 3,531 in-state trials (32.2%) are recruiting, against 37% nationally (-4.8 percentage points). Counts include every study with at least one recorded site in the state.
-
New Haven dominates Connecticut's trial geography.
New Haven lists 1,953 of 3,531 in-state trials (55.3%) across 543 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Connecticut.
77 of 3,531 in-state trials (2.2%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
One sponsor accounts for a large share of Connecticut trials.
Yale University appears on 511 of 3,531 in-state trials (14.5%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,589 Connecticut trials carry a completed status.
1,589 of 3,531 (45%) are completed. The open share above is the remainder that still lists recruiting.
Where trials run in Connecticut
New Haven carries 1,953 of Connecticut's 3,531 indexed trials (55%) across 543 named sites, ahead of Hartford at 529. 8 cities clear five listed trials, together naming 1,037 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| New Haven | 1,953 | 543 |
| Hartford | 529 | 130 |
| Farmington | 203 | 76 |
| Stamford | 175 | 81 |
| West Haven | 128 | 42 |
| Waterbury | 113 | 48 |
| Danbury | 104 | 63 |
| Norwalk | 101 | 54 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Volume high
Connecticut indexes 3,531 in-state trials (p67 by registry volume among 52 states with sites).
Connecticut: in-state trial volume sits in the high tercile
Sites spread across 8 cities with five or more listed trials, led by New Haven (1,953, 55% of the state total) and Hartford (529), together naming 1,037 distinct research locations.
Phase mix: 927 Phase 3 vs 810 Phase 2 (balanced across stages).
Top condition: Breast Cancer (77 trials); top sponsor Yale University (511).
high-volume · mid-open figures (3,531 trials · 32% open) describe registry geography under the volume high read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Connecticut on in-state trial volume
Cross-state peers under the volume high read (high-volume · mid-open), not the same-state browse list.
Similar high-volume hubs (± open share)
- Tennessee · 3,520 trials · 33% recruiting
- New Jersey · 3,402 trials · 34% recruiting
- Indiana · 3,113 trials · 29% recruiting
- Alabama · 4,168 trials · 29% recruiting
- Virginia · 2,598 trials · 40% recruiting
Similar mid-open peers (± trial volume)
- Kentucky · 32% recruiting · 2,183 trials
- Georgia · 32% recruiting · 5,195 trials
- Missouri · 33% recruiting · 4,116 trials
- Washington · 33% recruiting · 2,795 trials
- North Carolina · 33% recruiting · 5,625 trials